Call Options

13 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q2 2023

Aug 14, 2023

BUY
$15.48 - $35.0 $1,548 - $3,500
100 New
100 $2,000
Q2 2022

Aug 15, 2022

BUY
$3.74 - $10.66 $29,546 - $84,214
7,900 New
7,900 $33,000
Q4 2021

Feb 14, 2022

SELL
$15.2 - $35.51 $819,280 - $1.91 Million
-53,900 Closed
0 $0
Q4 2021

Feb 14, 2022

SELL
$15.2 - $35.51 $1.49 Million - $3.49 Million
-98,200 Reduced 64.56%
53,900 $1.02 Million
Q3 2021

Nov 15, 2021

BUY
$21.78 - $40.45 $3.31 Million - $6.15 Million
152,100 New
152,100 $5.06 Million
Q3 2021

Nov 15, 2021

SELL
$21.78 - $40.45 $3.08 Million - $5.73 Million
-141,600 Closed
0 $0
Q2 2021

Aug 16, 2021

BUY
$32.5 - $48.96 $4.6 Million - $6.93 Million
141,600 New
141,600 $5.49 Million
Q1 2021

May 14, 2021

SELL
$41.61 - $54.3 $3.89 Million - $5.08 Million
-93,500 Closed
0 $0
Q1 2021

May 14, 2021

BUY
$41.61 - $54.3 $3.89 Million - $5.08 Million
93,500 New
93,500 $4.51 Million
Q1 2020

May 15, 2020

SELL
$7.14 - $15.99 $357,000 - $799,500
-50,000 Closed
0 $0
Q1 2019

May 15, 2019

BUY
$4.02 - $8.04 $200,999 - $401,999
50,000 New
50,000 $402,000
Q4 2018

Feb 14, 2019

SELL
$3.44 - $5.76 $258,000 - $432,000
-75,000 Closed
0 $0
Q2 2018

Aug 14, 2018

BUY
$12.5 - $15.0 $937,500 - $1.13 Million
75,000 New
75,000 $986,000

Others Institutions Holding TGTX

About TG THERAPEUTICS, INC.


  • Ticker TGTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 145,274,000
  • Market Cap $4.29B
  • Description
  • TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...
More about TGTX
Track This Portfolio

Track Parallax Volatility Advisers, L.P. Portfolio

Follow Parallax Volatility Advisers, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Parallax Volatility Advisers, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Parallax Volatility Advisers, L.P. with notifications on news.